Zanubrutinib Plus BR in Newly Diagnosed Symptomatic WM
Condition: Waldenstrom Macroglobulinemia Intervention: Drug: Zanubrutinib, Bendamustine and Rituximab Sponsor: Institute of Hematology & Blood Diseases Hospital Recruiting
Source: ClinicalTrials.gov - Category: Research Source Type: clinical trials
More News: Hematology | Hospitals | Macroglobulinemia | Research | Rituxan | Waldenstrom's Macroglobulinemia